Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections
Abstract
BACKGROUND
Imipenem/cilastatin/relebactam (IMI/REL), a fixed-dose combination of imipenem/cilastatin with the β-lactamase inhibitor relebactam, has broad gram-negative coverage. Prospectively obtained safety and efficacy data in neonates and children are needed.
METHODS
Children (birth to <18 years old) with hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI), including pyelonephritis, were enrolled in an open-label, randomized, active-controlled, multinational phase 2/3 trial (ClinicalTrials.gov: NCT03969901). Participants were randomized 3:1 to IMI/REL or active-control, standard-of-care antibacterial therapy for 7-14 days (HABP/VABP; intravenous [IV] only) or 5-14 days (cIAI, cUTI; with oral step-down permitted after 3 days of IV). The primary endpoint was safety, assessed through 14 days after the end of therapy (EOT) as adverse events (AEs) and AE-related discontinuations of IV therapy. Clinical and microbiologic responses were also assessed at EOT and follow-up visits. This was an estimation study without hypothesis testing.
RESULTS
Eighty-six children were randomized to IMI/REL and 29 to active control. AEs were reported in 67.1% of IMI/REL versus 50.0% of active control arm participants (treatment difference: 17.1% [95% confidence interval: -3.5, 37.2]), leading to 3 versus 0 discontinuations of IV therapy, respectively. Treatment outcomes were generally…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.